Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
      Description

      This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

      Conditions
      Advanced BRAFV600 Wild-type Melanoma
      Talk to us
      TERMINATED
      Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
      Description

      This phase II trial studies how well binimetinib and nivolumab work in treating patients with BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving binimetinib and nivolumab together may work better in treating patients with melanoma compared to nivolumab alone.

      Conditions
      Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous MelanomaMetastatic Cutaneous MelanomaPathologic Stage III Cutaneous Melanoma AJCC V8Pathologic Stage IIIA Cutaneous Melanoma AJCC V8Pathologic Stage IIIB Cutaneous Melanoma AJCC V8Pathologic Stage IIIC Cutaneous Melanoma AJCC V8Pathologic Stage IIID Cutaneous Melanoma AJCC V8Pathologic Stage IV Cutaneous Melanoma AJCC V8Unresectable Cutaneous Melanoma
      Talk to us